• 1.

    Sukumar S, et al. Thrombotic thrombocytopenic purpura: Pathophysiology, diagnosis, and management. J Clin Med 2021; 10:536. doi: 10.3390/jcm10030536

  • 2.

    Little DJ, et al. Long-term kidney outcomes in patients with acquired thrombotic thrombocytopenic purpura. Kidney Int Rep 2017; 2:10881095. doi: 10.1016/j.ekir.2017.06.007

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Zheng XL, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost 2020; 18:24862495. doi: 10.1111/jth.15006

  • 4.

    Zheng XL, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost 2020; 18:24962502. doi: 10.1111/jth.15010

  • 5.

    Bendapudi PK, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: A cohort study. Lancet Haematol 2017; 4:e157-e164. doi: 10.1016/S2352-3026(17)30026-1

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Wynick C, et al. Validation of the PLASMIC score for predicting ADAMTS13 activity <10% in patients with suspected thrombotic thrombocytopenic purpura in Alberta, Canada. Thromb Res 2020; 196:335339. doi: 10.1016/j.thromres.2020.09.012

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Scully M, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019; 380:335346. doi: 10.1056/NEJMoa1806311

  • 8.

    Goshua G, et al. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021; 137:969976. doi: 10.1182/blood.2020006052

    • Crossref
    • Search Google Scholar
    • Export Citation

Thrombotic Thrombocytopenic Purpura International Society on Thrombosis and Haemostasis Guidelines for Diagnosis and Treatment

  • 1 Anitha Vijayan, MD, is Professor of Medicine, Division of Nephrology, Washington University in St. Louis, MO.
Restricted access
Save